| A phase II study of (18)F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva®); objective and symptomatic responses at 6 and 12weeks. | |
| | |
MedLine Citation:
|
PMID: 22119198 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: The aim of this study was to assess if (18)F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)-CT scanning could minimise the time non-responding patients were exposed to erlotinib (Tarceva®). METHODS: Patients were selected for clinical factors that would predict response to erlotinib. A FDG PET-CT and diagnostic contrast-enhanced (traditional) CT scan were carried out at baseline, and then a FDG PET-CT at 6weeks and a traditional CT at 12weeks were repeated. The primary end-point was rate of early progression in patients after 6weeks, of which a minimum 12 out of 35 were required to make the study worthwhile. The responses at 6 (PET-CT) and 12weeks (traditional CT) were compared and correlated with symptomatic response at both these time points. RESULTS: Forty seven patients were recruited with 38 and 33 patients assessable by FDG PET-CT at 6weeks and traditional CT at 12weeks, respectively. There was good correlation between Partial response (PR) at both time points and all 10 patients who had a PR at 12weeks had a PR at 6weeks. Of the 13 patients with progressive disease (PD) at 12weeks, seven had PD at 6weeks and could have had their treatment stopped early. No evaluable patient with stable disease (SD) (8/38) or PD (9/38) on FDG PET-CT at 6weeks went on to have a later response. Symptomatic response at 6 or 12weeks did not correlate well with objective response on scanning at either time point. CONCLUSIONS: The primary end-point of this study was met as >12 (15/38) patients could have stopped treatment early on the basis of the FDG PET-CT scan result. A FDG PET-CT evaluable response of SD or PD at 6weeks does predict future lack of response. No correlation was found between response and symptomatic response at either 6 or 12weeks. |
| | |
Authors:
|
M E R O'Brien; J S Myerson; J I G Coward; M Puglisi; L Trani; A Wotherspoon; B Sharma; G Cook; S Ashley; R Gunapala; S Chua; S Popat |
Related Documents
:
|
9894978 - Universal calibration of surgical instruments for spinal stereotaxy. 22268208 - Meniscal tear configurations: categorization with 3d isotropic turbo spin-echo mri comp... 9699078 - Assessment of 3-dimensional magnetic resonance imaging fast low angle shot images for c... 15257478 - High-resolution laser surface scanning for patient registration in cranial computer-ass... 16200568 - Quantification of cartilage biomechanical and biochemical properties via t1rho magnetic... 21937618 - Development of a fine thermocouple-needle system for real-time feedback of thermal tumo... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-11-24 |
Journal Detail:
|
Title: European journal of cancer (Oxford, England : 1990) Volume: - ISSN: 1879-0852 ISO Abbreviation: - Publication Date: 2011 Nov |
Date Detail:
|
Created Date: 2011-11-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9005373 Medline TA: Eur J Cancer Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011 Elsevier Ltd. All rights reserved. |
Affiliation:
|
Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The effectiveness of anaerobic digestion in removing estrogens and nonylphenol ethoxylates.
Next Document: A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: An Innov...